Investment Analysts’ Recent Ratings Changes for Uniqure (QURE)

Uniqure (NASDAQ: QURE) recently received a number of ratings updates from brokerages and research firms:

  • 10/19/2018 – Uniqure was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/18/2018 – Uniqure had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock. They wrote, “We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels.””
  • 10/17/2018 – Uniqure was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
  • 10/11/2018 – Uniqure was given a new $48.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/10/2018 – Uniqure was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $33.00 price target on the stock. According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
  • 10/9/2018 – Uniqure was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/3/2018 – Uniqure was given a new $58.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 9/28/2018 – Uniqure was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/24/2018 – Uniqure had its price target raised by analysts at HC Wainwright from $42.00 to $48.00. They now have a “buy” rating on the stock. They wrote, “Our new $48 price target, is based on a 13-year DCF analysis that incorporates rNPV of two pipeline products, including: (1) Hemophilia B at a 70% POS driven by company’s clinical update as of September 23, 2018, vs. prior 65%; and (2) 5% POS. We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $981M, upped from $820M previously, during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents a 50% of the overall commercial opportunity.””
  • 8/23/2018 – Uniqure was given a new $42.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock. They wrote, “Our $42 price target is based on a 13-year DCF analysis of the Hemophilia B (65% (5% POS). We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $820M during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents a 50% of the overall commercial opportunity.””
  • 8/23/2018 – Uniqure was given a new $58.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

QURE stock opened at $28.10 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -9.56 and a beta of 0.27. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.36 and a quick ratio of 8.36. Uniqure NV has a 12 month low of $11.55 and a 12 month high of $43.23.

Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.04. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. On average, sell-side analysts expect that Uniqure NV will post -2.44 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. California Public Employees Retirement System acquired a new stake in shares of Uniqure during the 1st quarter worth approximately $332,000. Jane Street Group LLC acquired a new stake in shares of Uniqure during the 1st quarter worth approximately $224,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Uniqure by 276.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after buying an additional 4,700 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Uniqure by 242.8% during the 1st quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after buying an additional 538,031 shares during the last quarter. Finally, Financial Gravity Wealth Inc. acquired a new stake in shares of Uniqure during the 1st quarter worth approximately $177,000. Institutional investors and hedge funds own 59.32% of the company’s stock.

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Further Reading: What Are Treasury Bonds?

Receive News & Ratings for Uniqure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply